Brought to you by 
SynCore gets rights to Medigene's EndoTAG-1
30 Jan 2023
Executive Summary
Medigene AG (therapeutics for cancer and autoimmune diseases) has granted SynCore Biotechnology Co. Ltd. (cancer and ophthalmic disease drug development; division of Sinphar Pharmaceutical Group) exclusive rights to co-develop and sell its EndoTAG-1 oncology treatment in Asia, Australia, and New Zealand. Medigene retains rights in the rest of the world.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SynCore gets rights to Medigene's EndoTAG-1
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice